Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model

Cancer Letters

Volumn 324, Issue 2, 2012, Pages 179-185

  Ni, Xiaoling ^a,b   Yang, Jingxuan ^a   Li, Min ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b FUDAN UNIVERSITY   (China)

Author keywords

Combinational therapy; Distal pancreatectomy; Imaging; Mouse model; Pancreatic cancer; Surgical resection

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; EARLY INTERVENTION; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IMAGE DISPLAY; IMAGING SYSTEM; MALE; MOUSE; NONHUMAN; OVERALL SURVIVAL; PANCREAS CANCER; PANCREAS RESECTION; PRIORITY JOURNAL; QUALITY OF LIFE; SURGICAL APPROACH; SURVIVAL RATE; SURVIVAL TIME; TUMOR GROWTH; TUMOR RECURRENCE; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL TRACKING; GREEN FLUORESCENT PROTEINS; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, NUDE; PANCREATECTOMY; PANCREATIC NEOPLASMS; TIME FACTORS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS; MUS MUSCULUS;

EID: 84864385906     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.05.013     Document Type: Article

References (26)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2012, 62(2012):10-29.
2. Shi S., Yao W., Xu J., Long J., Liu C., Yu X. Combinational therapy: new hope for pancreatic cancer?. Cancer Lett. 2012, 317:127-135.
3. Izeradjene K., Combs C., Best M., Gopinathan A., Wagner A., Grady W.M., Deng C.X., Hruban R.H., Adsay N.V., Tuveson D.A., Hingorani S.R. Kras(G12D) and Smad4/Dpc4 haploinsufficiency cooperate to induce mucinous cystic neoplasms and invasive adenocarcinoma of the pancreas. Cancer Cell 2007, 11:229-243.
4. Hingorani S.R., Wang L., Multani A.S., Combs C., Deramaudt T.B., Hruban R.H., Rustgi A.K., Chang S., Tuveson D.A. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005, 7:469-483.
5. Aguirre A.J., Bardeesy N., Sinha M., Lopez L., Tuveson D.A., Horner J., Redston M.S., DePinho R.A. Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev. 2003, 17:3112-3126.
6. Eibl G., Reber H.A. A xenograft nude mouse model for perineural invasion and recurrence in pancreatic cancer. Pancreas 2005, 31:258-262.
7. Torgenson M.J., Shea J.E., Firpo M.A., Dai Q., Mulvihill S.J., Scaife C.L. Natural history of pancreatic cancer recurrence following "curative" resection in athymic mice. J. Surg. Res. 2008, 149:57-61.
8. Li M., Zhang Y., Bharadwaj U., Zhai Q.J., Ahern C.H., Fisher W.E., Brunicardi F.C., Logsdon C.D., Chen C., Yao Q. Down-regulation of ZIP4 by RNA interference inhibits pancreatic cancer growth and increases the survival of nude mice with pancreatic cancer xenografts. Clin. Cancer Res. 2009, 15:5993-6001.
9. Li M., Zhang Y., Liu Z., Bharadwaj U., Wang H., Wang X., Zhang S., Liuzzi J.P., Chang S.M., Cousins R.J., Fisher W.E., Brunicardi F.C., Logsdon C.D., Chen C., Yao Q. Aberrant expression of zinc transporter ZIP4 (SLC39A4) significantly contributes to human pancreatic cancer pathogenesis and progression. Proc. Natl. Acad. Sci. USA 2007, 104:18636-18641.
10. Zhang Y., Bharadwaj U., Logsdon C.D., Chen C., Yao Q., Li M. ZIP4 regulates pancreatic cancer cell growth by activating IL-6/STAT3 pathway through zinc finger transcription factor CREB. Clin. Cancer Res. 2010, 16:1423-1430.
11. Zhang Y., Chen C., Yao Q., Li M. ZIP4 upregulates the expression of neuropilin-1, vascular endothelial growth factor, and matrix metalloproteases in pancreatic cancer cell lines and xenografts. Cancer Biol. Ther. 2010, 9:235-241.
12. Tan M.H., Shimano T., Chu T.M. Differential localization of human pancreas cancer-associated antigen and carcinoembryonic antigen in homologous pancreatic tumoral xenograft. J. Natl. Cancer Inst. 1981, 67:563-569.
13. Tan M.H., Chu T.M. Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumour Biol. 1985, 6:89-98.
14. Chen W.H., Horoszewicz J.S., Leong S.S., Shimano T., Penetrante R., Sanders W.H., Berjian R., Douglass H.O., Martin E.W., Chu T.M. Human pancreatic adenocarcinoma: in vitro and in vivo morphology of a new tumor line established from ascites. In vitro 1982, 18:24-34.
15. Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., Smith D.B., Langley R.E., Verma M., Weeden S., Chua Y.J., Participants M.T. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006, 355:11-20.
16. Kim J.S., Hur H., Kim N.K., Kim Y.W., Cho S.Y., Kim J.Y., Min B.S., Ahn J.B., Keum K.C., Kim H., Sohn S.K., Cho C.H. Oncologic outcomes after radical surgery following preoperative chemoradiotherapy for locally advanced lower rectal cancer: abdominoperineal resection versus sphincter-preserving procedure. Ann. Surg. Oncol. 2009, 16:1266-1273.
17. Roh M.S., Colangelo L.H., O'Connell M.J., Yothers G., Deutsch M., Allegra C.J., Kahlenberg M.S., Baez-Diaz L., Ursiny C.S., Petrelli N.J., Wolmark N. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J. Clin. Oncol. 2009, 27:5124-5130.
18. Sebag-Montefiore D., Stephens R.J., Steele R., Monson J., Grieve R., Khanna S., Quirke P., Couture J., de Metz C., Myint A.S., Bessell E., Griffiths G., Thompson L.C., Parmar M. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009, 373:811-820.
19. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., Michalski W., Bebenek M., Kryj M. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br. J. Surg. 2006, 93:1215-1223.
20. R.K. Wong, V. Tandan, S. De Silva, A. Figueredo, Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst. Rev. (2007) CD002102.
21. Liu S., Ballian N., Belaguli N.S., Patel S., Li M., Templeton N.S., Gingras M.C., Gibbs R., Fisher W., Brunicardi F.C. PDX-1 acts as a potential molecular target for treatment of human pancreatic cancer. Pancreas 2008, 37:210-220.
22. Ni X., Long J., Cen P., Chen L., Yang J., Li M. Pancreatic cancer tumour initiating cells: the molecular regulation and therapeutic values. J. Cell Mol. Med. 2012, 16:988-994.
23. Ji Q., Hao X., Zhang M., Tang W., Yang M., Li L., Xiang D., Desano J.T., Bommer G.T., Fan D., Fearon E.R., Lawrence T.S., Xu L. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS ONE 2009, 4:e6816.
24. Liu S.H., Patel S., Gingras M.C., Nemunaitis J., Zhou G., Chen C., Li M., Fisher W., Gibbs R., Brunicardi F.C. PDX-1: demonstration of oncogenic properties in pancreatic cancer. Cancer 2011, 117:723-733.
25. Yu X., Zhang Y., Chen C., Yao Q., Li M. Targeted drug delivery in pancreatic cancer. Biochim. Biophys. Acta 1805, 2010:97-104.
26. Long J., Zhang Y., Yu X., Yang J., LeBrun D.G., Chen C., Yao Q., Li M. Overcoming drug resistance in pancreatic cancer. Expert Opin. Ther. Targets 2011, 15:817-828.